Skip to main content
. 2023 Nov 9;49(12):1467–1478. doi: 10.1007/s00134-023-07247-w

Table 2.

Secondary clinical outcomes and serious adverse events

Randomization
Methylprednisolone, N = 68 Placebo, N = 69 p value
Secondary outcomes
Mortality, hospital discharge, n (%) 16 (24%) 24 (35%) 0.15
Mortality, 180 days, n (%) 17 (25%) 25 (36%) 0.15
CPCa score at discharge from hospital among patients alive at discharge, n (%) 0.17
 1 30 (58%) 34 (76%)
 2 15 (29%) 7 (16%)
 3 7 (13%) 4 (8.9%)
mRSb score at discharge from hospital among patients alive at discharge, n (%) 0.65
 0 14 (27%) 13 (29%)
 1 14 (27%) 13 (29%)
 2 10 (20%) 11 (24%)
 3 8 (16%) 6 (13%)
 4 5 (9.8%) 1 (2.2%)
 5 0 (0%) 1 (2.2%)
Serious adverse eventsc
Patients with ≥ 1 SAE, n (%) 35 (51%) 37 (54%) 0.80
Infection, n (%) 5 (7.4%) 4 (5.8%) 0.74
Bleeding, n (%) 0 (0%) 4 (5.8%) 0.12
Dialysis, n (%) 2 (2.9%) 1 (1.4%) 0.62
Electrolyte, n (%) 2 (2.9%) 1 (1.4%) 0.62
Metabolic, n (%) 1 (1.5%) 0 (0%) 0.50
Arrhytmia, n (%) 7 (10%) 10 (14%) 0.46
Seizures, n (%) 12 (18%) 13 (19%) 0.86

CPC cerebral performance categories, mRS modified Rankin Score, SAE serious adverse event

aRange from 1 to 5 with higher scores indicating greater disability with 3 or 4 being severe disability, coma or vegetative state and 5 being death

bRange from 0 to 6 with higher scores indicating greater degree of disability or dependence in daily activities with 0 being no symptoms and 6 being death

cAdverse event leading to prolonged hospitalization or a life-threatening condition requiring re-hospitalization or death